You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    SBC: SAVARA INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Development of RLIP76 protein as a Radiation Countermeasure

    SBC: TERAPIO            Topic: NIAID

    DESCRIPTION (provided by applicant): There remains a critical need for medicines that can counteract the toxic effects of radiation exposure. Terapio is developing a recombinant protein, RLIP76, for use as a radioprotectant for workers, military personnel, or civilians that are either in imminent danger of radiation exposure, or have already been exposed. In research carried out at the Unive ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Delivery system development for a reservoir targeted Lyme disease vaccine

    SBC: FoodSource Lure Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tickvector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme di ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Biomarker Quantitation by NP-MS Tissue Imaging.

    SBC: IONWERKS INC            Topic: NIDA

    DESCRIPTION provided by applicant MALDI tissue imaging when enabled by Nanoparticulate NP Matrix implantation is maturing into a useful preclinical tool for biomarker and drug discovery in our laboratory and at NIDA IRP Quantitatively reproducible images from serial coronal sections suggest that relative quantitation is now possible in rodent models of disease and injury Nanoparticulate ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation and Production of a Multivalent Adenoviral Plague Vaccine

    SBC: NORWELL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The final objective of this Phase II SBIR is to complete preclinical studies of a trivalent adenoviral vaccine against plague in preparation for human clinical trials. The plague vaccine project was selected in responseto the growing concern surrounding the organism's possible use in a terrorism event. The NIAID and CDC, in response to this threat, has cla ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): With recent radiation release from reactors in Japan and increasing probability of nuclear detonation somewhere in the world, there is a critical need for development of effective medicinal counter-measures that can bedelivered after exposure to prevent radiation-induced mortality. Adding to this need, mortality increases significantly when radiation is combine ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Neural Plasticity for the Treatment of Tinnitus

    SBC: MICROTRANSPONDER, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): This is a proposal to conduct a multi-center, double-blind, sham-controlled partial cross-over interventional study to test safety and efficacy of our novel tinnitus therapy. The tinnitus field generally accepts that elevated synchronous spontaneous activity in the auditory cortex may account for the tinnitus percept that arises following hearing loss. Followin ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A New Tool Kit for Whole-Genome Mapping and Complementation in Drosophila

    SBC: GENETIVISION CORPORATION            Topic: NIGMS

    DESCRIPTION (provided by applicant): The ultimate goal of this proposal is to generate, maintain, and distribute a new collection of duplication stocks that covers nearly the entire euchromatic autosomal portion of the Drosophila melanogaster genome. Sincethis collection will represent a powerful new set of tools that will benefit virtually all Drosophila geneticists, t is likely that there will b ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Enabling use of blood spot cards for accurate high throughput Fragile X screening

    SBC: ASURAGEN, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop accurate, rapid, high throughput and cost-effective screening for fragile X syndrome (FXS) and related disorders. FXS is the most common known genetic cause of autism andinherited intellectual disability, and affects roughly 1 in 4,000 males and 1 in 6,000 females. The incidence of fragile X carriers is as high a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR Topic 291

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NCI

    Not Available

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government